KBP is developing an innovative pipeline of New Chemical Entities with known mechanisms of action in areas of unmet medical need in Cardiovascular, Infectious Disease, Respiratory, Inflammatory and Autoimmune diseases.

KBP-5074 for CV disease/Hypertension in CKD patients – Initiating global Phase 2b in Q1 2018

KBP-7072 for multiple drug resistant infections – Finish Phase 1 – Ready for global Phase 2

KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD – IND Approved & Ready for Phase 1

Read More

• Brian P. McVeigh, CPA, CMA, CLP, MBA, Chief Executive Officer
• David N Gordon, MB ChB,CMO
• Fred Yang, PhD,CDO
• Vince Benn, PhD/MBA,VP
• Pual Chow, PhD,VP
• Jay (Xu-Jie) Zhang, PhD,VP
• Wayne W. Lai, PhD,VP

• George Bakris, MD (US)
• John McMurray, MD (UK)
• Bertram Pitt, MD (US)
• Ricard Wunderink, MD (US)
• Faiez Zannad, MD (FR)

Read More

KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive Officer

KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.

Careers Information updated on 27 July, 2017

Positive FDA Type B Meeting on KBP-5074

KBP-7072 obtained QIDP and Fast Track Designations

Read More

Contact Us

Fred Yang, Ph.D, Chief Development Officer          fred.yang@kbpbiosciences.com

116 Village Blvd., Suite 210 Princeton, NJ 08540      Phone: (609) 531-0889(Office) / (267)980-9451(Cell)